Filing Details

Accession Number:
0000899243-21-002906
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-22 16:05:07
Reporting Period:
2021-01-20
Accepted Time:
2021-01-22 16:05:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1797336 Ayala Pharmaceuticals Inc. AYLA Biological Products, (No Disgnostic Substances) (2836) 823578375
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1811354 B. Gary Gordon Oppenheimer 4
Rehovot L3 7670104
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-20 3,000 $5.16 11,520 No 4 M Direct
Common Stock Disposition 2021-01-20 3,000 $15.03 8,520 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2021-01-20 3,000 $0.00 3,000 $5.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
92,000 2029-09-19 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. This option vested and became exercisable as to 25% of the underlying shares of common stock on August 1, 2020 and will become vested and exercisable as to the remainder of the shares in 12 equal quarterly installments thereafter.